<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194437</url>
  </required_header>
  <id_info>
    <org_study_id>OCS-LVR-092019</org_study_id>
    <nct_id>NCT04194437</nct_id>
  </id_info>
  <brief_title>OCS Liver DCD Trial</brief_title>
  <official_title>Prospective Trial to Evaluate the Effectiveness of The Portable Organ Care System (OCS) Liver for Preserving, Optimizing and Assessing Currently Seldom Utilized DCD Donor Livers for Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TransMedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TransMedics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and effectiveness of the OCS Liver System to preserve, optimize the&#xD;
      condition, and assess levers from DCD donors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and effectiveness of the OCS™ Liver to preserve, optimize the&#xD;
      condition and assess livers from DCD donors that currently are seldom used for liver&#xD;
      transplants due to limitations of cold static storage with extended warm ischemic time and&#xD;
      older donors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">September 19, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver graft survival through 6 months post-transplant</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of graft survival as defined per UNOS data collection criteria for graft status after liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of donor liver utilization after OCS liver perfusion</measure>
    <time_frame>OCS liver perfusion</time_frame>
    <description>The number of eligible donor livers that were instrumented and perfused on OCS liver system and successfully transplanted, divided by the number of eligible donor livers that were instrumented and perfused on OCS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ischemic biliary cholangiopathy at 6 months post-transplant</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of ischemic biliary complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Early Allograft Dysfunction (EAD) or primary non-function</measure>
    <time_frame>7 days</time_frame>
    <description>Evaluation of EAD via AST, Bilirubin and INR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>Day 30</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>6 months</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>12 months</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>24 months</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>36 months</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>48 months</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient and graft survival</measure>
    <time_frame>60 months</time_frame>
    <description>Survival as determined by follow-up visit/call with patient or health care provider.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Liver Transplant</condition>
  <arm_group>
    <arm_group_label>OCS Preserved Livers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a single-arm trial of OCS preserved livers used for transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OCS Liver System</intervention_name>
    <description>The OCS Liver System will be used to preserve, optimize and assess livers from DCD donors.</description>
    <arm_group_label>OCS Preserved Livers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Registered primary liver transplant candidate&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Obtained informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute, fulminant liver failure&#xD;
&#xD;
          -  Prior solid organ or bone marrow transplant&#xD;
&#xD;
          -  Ventilator dependent on day of transplant/donor organ offer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Elbetanony, MD</last_name>
    <role>Study Director</role>
    <affiliation>TransMedics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa General</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

